UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): June 4, 2012
| CHINA BIOLOGIC PRODUCTS, INC. | ||
| (Exact name of registrant as specified in its charter) | ||
| Delaware | 001-34566 | 75-2308816 |
| (State or other jurisdiction of | (Commission File No.) | (IRS Employer ID No.) |
| incorporation or organization) | ||
18th Floor, Jialong International Building
19 Chaoyang
Park Road
Chaoyang District, Beijing 100125
People’s Republic of
China
(Address of Principal Executive Offices)
86 10 6598 3111
Registrant's telephone number,
including area code
____________________________________________________________
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 7.01 REGULATION FD DISCLOSURE.
On June 4, 2012, China Biologic Products, Inc. (the “Company”) issued a press release announcing its plan to attend the Jefferies 2012 Global Healthcare Conference (the “Conference”) in New York, NY on June 7, 2012. Copy of the press release and the presentation materials that the Company plans to use during the Conference, which the Company is furnishing to the Securities and Exchange Commission, are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated by reference herein.
The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The disclosure in this Current Report on Form 8-K, including the exhibits attached hereto, of any information (financial or otherwise) does not constitute an admission that such information is material.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
| Exhibit Number | Description |
| 99.1 | News release dated June 4, 2012 |
| 99.2 | Presentation of the Company, June 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 4, 2012
CHINA BIOLOGIC PRODUCTS, INC.
By: /s/ David (Xiaoying) Gao
David (Xiaoying) Gao
Chief Executive Officer
China Biologic to Attend Jefferies Healthcare Conference on June 7, 2012 in New York
BEIJING, China, June 4, 2012 /PRNewswire/ China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China, today announced that it will participate in the Jefferies 2012 Global Healthcare Conference on June 7, 2012 in New York.
Mr. Ming Yin, China Biologic's Vice President of Business Development, will present at the conference on Thursday, June 7 at 10:00 a.m. in Ballroom 1 at the Grand Hyatt New York Hotel, 109 East 42nd Street at Grand Central Terminal, New York.
Investors interested in meeting with China Biologic during the conference may contact their Jefferies representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in China.
China Biologic is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company’s website www.chinabiologic.com for additional information.
Source: China Biologic Products, Inc.
www.chinabiologic.com